TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04918173: Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Sponsor: Octapharma · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 38 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT04918173 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04918173 Rescue Dossier →